FindTrial
Sign In

A comparison of acute radiation skin complication in patients with locally advanced cervical cancer treated with pelvic irradiation between applied 3M Cavilon No-Sting Barrier Film versus silver sulfadiazine cream during irradiation

A comparison of acute radiation skin complication in patients with locally advanced cervical cancer treated with pelvic irradiation between applied 3M Cavilon No-Sting Barrier Film versus silver sulfadiazine cream during irradiation

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20161026002
Enrollment
285
Registered
2016-10-26
Start date
2017-02-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer stage IB2&#45

Interventions

Apply SSD at radiated area on 1st day of radiation and then twice daily until complete radiotherapy session,Spray NSBF at irradiated area on 1st day of radiation before start radiation and then every
Wednesday&#44
and Friday until complete radiotherapy session,Advise standard skin care during radiotherapy session
Active Comparator Drug,Active Comparator Drug,Active Comparator Behavioral
Silver Sulfadiazine cream (SSD),3M Cavilon No&#45
Sting Barrier Film (NSBF),Advise skin care

Sponsors

3M Thailand Limited
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Cervical cancer stage IB2-IVA Planned for definite concurrent chemoradiation Radiation field cover perineum

Exclusion criteria

Exclusion criteria: History of 3M Cavilon No-Sting Barrier Film allergy or irritation

Design outcomes

Primary

MeasureTime frame
Acute radiation skin complication 0-3 months after start radiation RTOG grade—

Secondary

MeasureTime frame
Acute radiation complication 0-3 months after start radiation RTOG grade—

Countries

Thailand

Contacts

Public ContactWarissara Rongthong

THASTRO

warissara.ron@gmail.com+66872018848

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026